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Protein misfoldingType I galactosemia is a genetic disorder that is caused by the impairment of galactose-1-phosphate
uridylyltransferase (GALT; EC 2.7.7.12). Although a large number of mutations have been detected through
genetic screening of the human GALT (hGALT) locus, for many it is not known how they cause their effects.
The majority of these mutations are missense, with predicted substitutions scattered throughout the enzyme
structure and thus causing impairment by other means rather than direct alterations to the active site. To
clarify the fundamental, molecular basis of hGALT impairment we studied ﬁve disease-associated variants
p.D28Y, p.L74P, p.F171S, p.F194L and p.R333G using both a yeast model and puriﬁed, recombinant proteins.
In a yeast expression system there was a correlation between lysate activity and the ability to rescue growth
in the presence of galactose, except for p.R333G. Kinetic analysis of the puriﬁed proteins quantiﬁed each
variant's level of enzymatic impairment and demonstrated that this was largely due to altered substrate
binding. Increased surface hydrophobicity, altered thermal stability and changes in proteolytic sensitivity
were also detected. Our results demonstrate that hGALT requires a level of ﬂexibility to function optimally
and that altered folding is the underlying reason of impairment in all the variants tested here. This indicates
that misfolding is a common, molecular basis of hGALT deﬁciency and suggests the potential of pharmacolog-
ical chaperones and proteostasis regulators as novel therapeutic approaches for type I galactosemia.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Type I galactosemia (OMIM #230400) is a genetic disorder that is
caused by impairment of galactose-1-phosphate uridylyltransferase
(GALT; EC 2.7.7.12) [1]. Two other forms of galactosemia are also
recognized: galactokinase deﬁciency (type II; OMIM #230200) and
UDP-galactose 4′-epimerase deﬁciency (type III; OMIM #230350)
[2,3]. GALT is involved in the metabolism of galactose and it catalyses
the reversible conversion of UDP-glucose and galactose-1-phosphate
to UDP-galactose and glucose-1-phosphate via an uridylated enzyme
intermediate [4,5]. Deﬁciency of human GALT (hGALT) is detected
through newborn screening in many developed countries minimizinghonic acid; BS3, suberic acid
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rights reserved.the acute pathology that can otherwise include jaundice, cataracts,
vomiting, diarrhea, hepatomegaly, sepsis and neonatal death [6]. Galac-
tose restriction in the diet can immediately mitigate or prevent these
acute manifestations, but does not appear to prevent longer-term
complications that include ovarian failure and disabilities in learning
and speech, among other problems [7]. The underlying mechanism of
these long-term pathologies is not fully known, and the role of accumu-
lated galactose-1-phosphate in the process remains controversial [8]. In
addition, understanding phenotype–genotype correlations is difﬁcult as
compound heterozygosity plays a role in disease [9]. This is because the
hGALT protein functions as a dimer (Fig. 1) [10–12]. However, recently
the level of predicted residual GALT activity associated with genotype
of a cohort of school-age children with type I galactosemia was
demonstrated to inﬂuence the level of scholastic achievement of those
students in mathematics [13].
To date, 264 variants have been reported from genetic screening
of the hGALT gene. Of these, 159 are missense mutations and for the
majority it is not known how they cause their effects [14,15]. The
most commonly detected severe mutant, Q188R, and selected others
have been studied using a yeast model [16–21] which has provided
useful information about the severity of each mutation in vivo.
However, detailed functional and structural analyses have been lack-
ing, as only a small number of variants have been studied in any detail
in vitro [12,22–27].
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Fig. 1. Structure of hGALT and location of mutants analysed in relation to active site. The homology-modelled structure of the hGALT dimer is presented as a cartoon. Each monomer
is coloured light orange or light green. The residues altered by the disease-associated mutations are highlighted in dark grey and presented in stick representations. The active site
residue, His-186 is also represented in a stick model and is highlighted in purple. This ﬁgure was visualised in PyMol (www.pymol.org) using PDB entry 1R3A [41].
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the active site of hGALT and therefore are predicted to affect catalysis di-
rectly, the majority are located elsewhere throughout the enzyme's
structure [28,29]. Computational analysis using a homology model of
hGALT has suggested that these mutations alter hydrogen bond net-
works and hydrophobic interactions. Decreased monomer stability
was predicted for over half of the studied variants, which suggests
that they may cause protein misfolding [28,29]. More recently it has
been shown that disease-associated mutants affect the expression and
solubility of hGALT in an Escherichia coli expression system. Molecular
dynamics simulations predicted that these mutations affect the overall
ﬂexibility of the enzyme thus altering substrate afﬁnity [30]. Similarly,
previous studies have shown that somemutants can cause temperature
sensitivity and decreased levels of expression in yeast [20,21]. Effects on
dimer formation have also been detected which further supports the
hypothesis that alterations in overall structure are involved [12,25].
Sincemisfolding has not been experimentally veriﬁed for themajor-
ity of hGALT mutants [15] ﬁve representative variants, p.D28Y, p.L74P,
p.F171S, p.F194L and p.R333G were studied here with the aim of
establishing whether, or not, this is a common feature of variants asso-
ciated with type I galactosemia. These variants have been previously
found to be associated with type I galactosemia (Table S1) and all ﬁve
variants are classiﬁed as pathogenic in the hGALT mutant database
[14]. Only p.F171S and p.L74P are located at the active site (Fig. 1) and
both have been shown to severely impair enzyme activity (Table S1)
[19,20,31]. The remaining three variants are located away from the ac-
tive site and all ﬁve have been included in a recentmolecularmodelling
study of variant GALT enzymes [29]. Thus the studied set represents a
diverse group of mutants, which have previously been clinically
characterised (Table S1) and subject to, at least, some theoretical anal-
ysis. Each of the ﬁve mutants was studied in terms of their effects in
vivo using an established yeast model and in vitro with the recombi-
nant, puriﬁed variant proteins from a bacterial expression system to
determine their stability, substrate binding, ability to dimerise and en-
zyme kinetics in the forward and reverse directions.
2. Materials & methods
2.1. Expression of hGALT alleles in yeast
Each hGALT allele was recreated by site-directed mutagenesis of
the centromeric yeast vector pMM22.hGALT as described previously[20,21] and conﬁrmed by dideoxy sequencing of the entire GALT open
reading frame. Creation and analysis of the F171S substitution has
been described previously in the context of other studies [19,20]. The
primers used to generate these alleles are listed in Table S2.
Each plasmid was transformed into each of two haploid strains of
Saccharomyces cerevisiae: JFy3747 [21], which is deﬁcient in GAL7, the
gene encoding endogenous yeast GALT [32], and JFy5555, which is
deﬁcient in GAL7 and also deﬁcient in GAL1 and GAL10, which encode
the endogenous yeast GALK and GALE enzymes, respectively [32].
JFy3747 was used as the host for all growth curve experiments, and
JFy5555 was used as the host for all biochemical studies performed
using yeast lysates. All yeast strains were grown on a medium lacking
tryptophan to maintain selection for the MM22-based plasmids.
2.2. Enzyme activities from soluble yeast lysates
GALT activity assays were performed using soluble protein lysates
from JFy5555 expressing each of the desired GALT alleles, essentially
as described previously [21] except that progress of the reaction was
quantiﬁed by monitoring the appearance of UDP-galactose (in nmol
UDP-gal/μg protein/min). Because the host yeast was deﬁcient in
GALK and GALE as well as in endogenous GALT there was essentially
no background conversion of UDP-glc to UDP-gal by GALE in the ab-
sence of GALT activity. The average ± SD (n = 3) of GALT enzyme
activity for yeast expressing each allele was normalized to the activity
level observed in yeast expressing wild-type hGALT from the same
plasmid backbone.
2.3. Yeast growth studies
Colonies of JFy3747 yeast expressing the desired alleles of hGALT
were cultured and assessed for growth in the wells of 96 well plates
using SGE-trp medium with and without 0.01% galactose, as described
previously [21]. OD600 readings from any wells that showed evidence
of air bubbles or clumping were excluded from analysis. The aver-
age ± SD of OD600 readings from 3 separate wells representing yeast
expressing each GALT allele and galactose condition were plotted.
2.4. Expression and puriﬁcation of recombinant proteins
The gene encoding hGALT was ampliﬁed by PCR from the IMAGE
clone [33] number 3922902 and was cloned into the NdeI and EcoRI
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a hexahistidine tag at the 5′ end. The insertion of the gene into the re-
combinant expression vector was veriﬁed by sequencing and
this plasmid was then transformed into E. coli Rosetta(DE3) (Merck,
Nottingham, UK). Single colonies resulting from this transformation
were picked and grown in 5 ml of LB (supplemented with
100 μg ml−1 ampicillin, 34 μg ml−1 chloramphenicol, 50 μM ZnCl2),
shaking at 30 °C overnight. This culture was then diluted into 1 L of
LB (supplemented with 100 μg ml−1 ampicillin, 34 μg ml−1 chlor-
amphenicol, 50 μM ZnCl2) and grown, shaking at 30 °C until A600nm
was between 0.6 and 1.0 (typically 6 h). At this point the culture
was induced with 1 mM IPTG at 15 °C and grown for a further 20 h.
Cells were harvested by centrifugation at 4200 ×g for 20 min and
cell pellets were resuspended in buffer R (50 mMHEPES, 5 mM imid-
azole, pH 7.5, 150 mM NaCl, 10% (v/v) glycerol, 5 mM DTT). These
suspensions were frozen at −80 °C until required.
The cell suspensions were thawed and the cells broken by sonica-
tion on ice (three 30 s pulses of 100 W with 30 s gaps in between for
cooling). The extract was centrifuged at 20,000 ×g for 20 min to re-
move insoluble material and the supernatant applied to a 1 ml nickel
agarose (Sigma, Poole, UK) column. Once this solution had passed
through, the column was washed with 20 ml buffer W (as buffer R,
expect with 500 mM NaCl and 20 mM imidazole) and the protein
was eluted with a 2 ml wash of buffer E (buffer W supplemented
with 250 mM imidazole). The eluate was further puriﬁed by size ex-
clusion chromatography on a Sephacryl S-300 (Pharmacia) column
(55 ml) at 4 °C with a mobile phase that consisted of 50 mM HEPES,
pH 7.5, 150 mM NaCl, 10% (v/v) glycerol, 5 mM DTT. A ﬂow rate of
1 ml min−1 was used and 1 ml fractions was collected. Control pro-
teins of known molecular mass were used to construct a standard
curve and, thus, determine the oligomeric state of hGALT. Protein
containing fractions, (judged by absorbance at 280 nm) corresponding
to themolecularmass of hGALT dimers (87 kDa), were pooled together.
These pooled fractions were then concentrated using Amicon Ultra-4
(Millipore) centrifugal ﬁltration devices (cut-off of 3 kDa) at 4 °C to a
ﬁnal volume of ≈600 μl. The protein solution was then divided into
30 μl aliquots and stored frozen at−80 °C.
The Quick Change protocol [34] was used to change the appropri-
ate codons in the expression vector. Successful mutagenesis was
veriﬁed by sequencing (MWG-Biotech, Ebersburg, Germany). These
mutated plasmids were used to express p.D28Y, p.L74P, p.F171S,
p.F194L and p.R333G-hGALT using the same protocol as used with
the wild-type protein.
Recombinant human UDP-glucose dehydrogenase was expressed
and puriﬁed as described [35]. The expression and puriﬁcation of all
proteins was monitored by 10% SDS-PAGE. All protein concentrations
were estimated using the Bradford assay [36] with bovine serum al-
bumin as a standard.
2.5. Spectroscopic measurements
Intrinsic ﬂuorescence of each hGALT variant was measured using
5.5 μM protein in 10 mM HEPES, pH 8.8 in a total volume of 180 μl.
The binding of 1-anilinonaphthalene-8-sulphonic acid (ANS-1) was
used to determine the degree of surface hydrophobicity with each
variant at 5 μM in 10 mM HEPES, pH 8.8 with 100 μM ANS-1 in a
total volume was 200 μl. Samples with ANS-1 were incubated at
room temperature in the dark for 30 min before measurement. Fluo-
rescence spectra were measured (in triplicate) at room temperature
using a Spectra Max Gemini X plate-reader ﬂuorimeter (Molecular
Devices, CA, USA) with excitation at 280 nm, emission 300–500 nm,
and a slit width of 10 nm for intrinsic ﬂuorescence. Excitation at
370 nm, emission 420–580 nm, and a slit width of 5 nm were carried
out for ANS-1 binding. Emission spectra were averaged for each var-
iant and corrected for the emission of buffer only or ANS-1 in buffer
only, as appropriate.2.6. Measurement of the steady state kinetic parameters for
galactose-1-phosphate uridylyltransferase
Enzymatic activities of the hGALT variants in the forward reaction
were determined using a spectrophotometric coupled assay based on
that described previously [19] which couples the production of glu-
cose 1-phosphate to its isomerization to glucose 6-phosphate and
subsequent NADP+-dependent oxidation of this compound. The stan-
dard reaction was performed at 37 °C and contained 10 mM HEPES,
pH 8.8, 5 mM DTT, 5 mM glucose 1,6-bisphosphate, 5 mM MgCl2,
0.8 mM NADP+, 0.03 mg glucose-6-phosphate dehydrogenase, and
0.4 mg of phosphoglucomutase. Assays were performed in triplicate
in a 96 well plate format each with a total volume of 150 μl. Kinetic
constants were determined for UDP-Glc by varying its concentration
from 0.01 to 1.0 mM while the concentration of Gal-1P was held at
a constant 1.0 mM. Conversely the kinetic constants for Gal-1P were
determined by varying its concentration from 0.01 to 2.0 mM while
UDP-Glc was held constant at 0.5 mM. The amount of NADPH
produced (detected by absorption at 340 nm) is equivalent to the
amount of Glc-1P formed.
Enzymatic activities of the hGALT variants in the reverse reaction
were also determined using a spectrophotometric coupled assay
based on that described previously [37] which couples the production
of UDP-glucose to the NAD+-dependent oxidation of this compound.
The standard reaction was performed at 37 °C and contained 10 mM
HEPES, pH 8.8, 5 mM DTT, 5 mM MgCl2, 10 mM NAD+, and 1.2 μM
human UDP-glucose dehydrogenase. Assays were performed in
triplicate in a 96 well plate format each with a total volume of
150 μl. Kinetic constants were determined for UDP-gal by varying
its concentration from 0.01 to 1.0 mM while the concentration of
Glc-1P was held at a constant 1.0 mM. Conversely the kinetic con-
stants of Glc-1P were determined by varying its concentration from
0.01 to 2.0 mM while UDP-gal was held constant at 0.5 mM. The
amount NADH produced, measured at 340 nm, is equivalent to
twice the amount of UDP-Glc formed [38].
All reactions were monitored at 340 nm for 40 min at 37 °C using
a Multiskan Spectrum spectrophotometer (Thermo Scientiﬁc). Con-
trols lacking either one or both substrates were routinely included,
for both forward and reverse kinetic assays, and always gave the
expected negative results.
The initial rate of product formation was plotted against substrate
concentration and analysed using non-linear curve ﬁtting of GraphPad
Prism (GraphPad Software, CA, USA). The data was ﬁtted to either
Michaelis–Menten Eq. (1), Michaelis–Menten with substrate inhibition
Eq. (2) or sigmoidal kinetics Eq. (3).
v ¼ V
app
max S½ 
Kappm þ S½ 
ð1Þ
where Vmaxapp is the apparent maximum, limiting rate and Kmapp is the ap-
parent Michaelis constant.
v ¼ V
app
max S½ 
Kappm þ S½  1þ S½ Kappi
  ð2Þ
where Kiapp is the apparent dissociation constant.
v ¼ V
app
max S½ h
Kapp0:5
h þ S½ h ð3Þ
where h is the Hill coefﬁcient and K0.5app is the concentration of substrate
to give a rate equal to half of Vmaxapp . [S] is the concentration of the varied
substrate for all equations. The goodness of ﬁt to these equations was
compared using the F test and results are reported for the best ﬁt to
the data.
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Before the addition of a chemical cross-linker, hGALT variants
(5 μM in 10 mM HEPES, pH 8.8) were incubated at 37 °C for 5 min
with and without ligands (1 mM). BS3 (Sigma) or glutaraldehyde
(Sigma) was then added to ﬁnal concentrations of 100 μM and
0.25% (v/v) respectively. Cross-linking was allowed to proceed for
30 min and was then halted by the addition of an equal volume of
SDS loading buffer (125 mM Tris–HCl, pH 6.8, 4% (w/v) SDS, 20% (v/v)
glycerol, 1% (w/v) dithiothreitol, 0.002% (w/v) bromophenol blue).
Samples were denatured at 95 °C for 5 min before analysis by 10%
SDS-PAGE.
2.8. Limited proteolysis
hGALT variants (5 μM in 10 mMHEPES, pH 8.8) were incubated at
37 °C for 5 min with and without ligands (1 mM). Thermolysin, tryp-
sin or chymotrypsin (Sigma), as indicated, was then added as ﬁnal
concentrations of 240 nM, 120 nM, and 24 nM respectively. Diges-
tion was carried out for 30 min and was stopped by the addition of
an equal volume of SDS loading buffer. Samples were denatured at
95 °C for 5 min before analysis by 15% SDS-PAGE.
2.9. Thermal inactivation of hGALT
Thermal inactivation of hGALT variants was judged kinetically
using the forward reaction setup described in Section 2.8. Aliquots
(100 μl) of each active variant hGALT at 0.5 μM were incubated in
10 mM HEPES, pH 8.8 for 15 min at temperatures ranging from 30
to 70 °C (5 °C increments). These aliquots were chilled in ice immedi-
ately after incubation and the residual activity was determined at
0.5 mM UDP-glucose and 1.0 mM galactose-1-phosphate with
50 nM hGALT. Measurements were carried on three independent as-
says for each temperature and the average activity was calculated
with standard deviations. These were normalized to the activity of
each variant at 30 °C.
2.10. Differential scanning ﬂuorimetry assay
Differential scanning ﬂuorimetry was carried out essentially as
previously described [39,40]. Protein samples were diluted in
10 mM HEPES, pH 8.8 to a ﬁnal concentration of 5 μM and any li-
gands used were added at a ﬁnal concentration of 1 mM. Sypro
orange (Sigma, Poole, UK) was diluted from a 5000× solution
(manufacturer's concentration deﬁnition) into a 50× solution with
10 mM HEPES, pH 8.8 and was mixed well prior to each use before
1 μl was added to each mixture. Reactions were set up in a total vol-
ume of 20 μl in 0.2 ml PCR tubes and controls of no protein added
were always included.
Reaction mixtures were loaded into a Rotor-Gene Q cycler
(Qiagen) and the following protocol was used: High resolution melt
run (460 nm source, 510 nm detector), 25 °C to 95 °C ramp with a
1 °C rise for each step and no gain optimisation. The melting temper-
atures, (Tm), were calculated using the inbuilt analysis software. The
shift in stability corresponding to the change of melting temperature,
ΔTm, for each variant and ligand binding was calculated using Eqs. (4)
and (5) respectively.
ΔTm ¼ Tm of WTð Þ  Tm of variantð Þ ð4Þ
ΔTm ¼ Tm of protein without ligandð Þ  Tm of protein with ligandð Þ
ð5Þ
To determine the signiﬁcance of the differences in Tm the one way
ANOVA with Dunnett comparison test was used.2.11. In silico analysis of variants
The homology model of hGALT, PDB 1R3A [41] was used to deter-
mine the location of altered residues. Additional homology models
of p.D28Y, p.L74P, p.F171S, p.F194L and p.R333G hGALT, based on
1R3A, were obtained from the hGALT mutant structure database
[28] (http://bioinformatica.isa.cnr.it/GALT/). Structures were viewed
using PyMol (http://www.pymol.org/).
Sequence alignment was carried out using ClustalW2 [42] and all
sequences were obtained from the UniProt database (http://www.
uniprot.org/). Conserved residues, and those involved in cofactor
and metal binding were identiﬁed with ClustalW2.
In determining the effects on stability of hGALT mutants the fol-
lowing programs were used: Dmutant [43], PoPMusic 2.1 [44], Cupsat
[45], SDM [46], Eris [47], Concoord/PBSA [48], I-Mutant 2.0 [49],
MuPro [50], and Mustab [51]. When appropriate, the structure 1R3A
was used. Both thermal and denaturation options were used of the
Cupsat server. Additionally both ﬂexible and inﬂexible backbone op-
tions were used of the Eris server. When using the SDM server the
mutant structures obtained from the hGALT mutant structure data-
base were used. The overall consensus of stability change was deter-
mined with the percentage of agreeing predictions. All predictions
were determined from the A chain contained in the coordinate ﬁles.
Prediction of intrinsically disordered regions in hGALT was carried
out usingmetaPrDOS [52] and Spine-D [53]; metaPrDOS uses a consen-
sus based approach using multiple predictors. Both predict the proba-
bility of disorder and those residues with a probability of 0.5 and
higher are deemed disordered. The regions predicted from these two
servers were mapped onto the homology model (1R3A) using PyMol.
The FTMap server [54] was used to predict any allosteric sites in
hGALT. This server predicts potential binding sites of proteins,
which can act as the starting pointing of identifying ‘druggable
hotspots’. In addition, this server can predict potential substrate bind-
ing and allosteric sites [55]. FTMap uses a fragment-based approach
that uses sixteen small organic molecules to map these potential
binding sites. This is based on a crystallographic approach (Multiple
Solvent Crystal Structures or MSCS) where structures are solved in a
number of different solvents containing organic solvents [54]. In addi-
tion to FTMap, both Q-SiteFinder and Pocket-Finder [56] were used to
predict potential binding pockets. The homology structure 1R3A was
submitted to these servers and the resulting sites were visualised
using PyMol.
3. Results
3.1. In silico analysis suggests alteration of overall protein charge, surface
hydrophobicity and monomer stability due to each amino acid substitution
Previously, a computational approach was used to understand
how 107 missense mutations cause their effects on hGALT structure
and this suggested changes in residue interactions, surface area and
stability [28,29]. Here we extended this work by using a number of
different protein analysis servers to predict how p.D28Y, p.L74P,
p.F171S, p.F194L and p.R333G affect hGALT structure and function.
This was done to improve the conﬁdence of our predictions since
each of the algorithms has different strengths and weaknesses [57].
Initial analysis using PolyPhen-2 [58] and SIFT [59] suggested that
all the mutations were “probably damaging” and “damaging” respec-
tively. In contrast only p.D28Y and p.R333G were predicted to have
altered overall charges and pI values of the linear protein chain as
predicted using the Protein Calculator version 3.3 (www.scripps.
edu/~cdputnam/protcalc.html). However, using the POPS server [60]
and the hGALT mutant dimer structures [28] all were predicted to
have increases in surface hydrophobicity (Table S3A). Further analy-
sis using a number of different protein stability prediction servers
suggested that each mutation results in stability changes of the
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Fig. 2. Yeast growth curves expressing each hGALT variant in the presence of 0.01% ga-
lactose. Cultures of gal7-null yeast expressing either WT, no hGALT, p.D28Y-hGALT,
p.L74P-hGALT, F171S-hGALT, F194L-hGALT or R333G-hGALT were inoculated into
96-wellplates in SGE-trp medium with the indicated amount of galactose added at
t = 0. Growth of each culture was monitored at OD600. Plotted values represent
means ± SD; n = 3.
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p.D28Y and p.F194L to be stabilised whereas p.L74P, p.F171S and
p.R333Gwere predicted to be destabilised (Table S3B). Previous stud-
ies using only two servers suggested that all are destabilised except
p.D28Y where no deﬁnite prediction could be made [28].
Taken together these analyses suggest that these residues are im-
portant in maintaining the overall structure of hGALT. Furthermore
protein sequence alignment revealed that L74, F171 and R333 were
strictly conserved across species, whereas D28 and F194 were not.
However, it was revealed that a hydrophilic residue (e.g. aspartate,
glutamate or serine) is always at position 28 and that F194 is con-
served in all except yeast, where it is a serine (Fig. S1).
3.2. Impact of disease-associated substitutions on hGALT activity
measured in soluble yeast lysates
As a ﬁrst assessment of the functional consequence of each of the
patient GALT alleles described here, we expressed each in the context
of a haploid strain of S. cerevisiae (baker's yeast), JFy5555, which is
deﬁcient in the entire endogenous Leloir pathway, and monitored
GALT activity measured in vitro in soluble cell lysates. Budding
yeast represents a good, eukaryotic model for inherited metabolic
diseases due to the organism's short generation time and the ease
with which it can be genetically modiﬁed [61–64]. However, it cannot
recapitulate multicellular or tissue level consequences. Here, we used
it to understand how the disease-associated mutations affect GALT
activity in a cellular context. Two of the patient alleles tested, L74P
and F171S, each demonstrated no detectable activity above back-
ground (Table 1). For L74P this was a new ﬁnding; for F171S this re-
sult had been observed previously as part of another study [19]. One
allele, R333G, demonstrated detectable, albeit residual (b1%), GALT
activity above background, and ﬁnally two alleles, D28Y and F194L,
each demonstrated >10% wild-type activity (Table 1).
3.3. Effect of each substitution on the ability of hGALT to rescue galactose
stressed yeast
As a test of function in vivo each patient allele was expressed in
the haploid yeast strain JFy3747 [21] which is missing endogenous
GALT but expresses endogenous galactokinase (Gal1p) and UDP-
galactose 4′-epimerase/galactose mutarotase (Gal10p). JFy3747 ex-
pressing each hGALT allele was inoculated into a medium containing
2% glycerol and 2% ethanol in the presence vs. absence of 0.01% galac-
tose. In the absence of galactose all of the cultures grewwell (data not
shown), but in the presence of 0.01% galactose clear distinctions were
evident. As expected from prior studies [16,20,21] yeast expressing
wild-type hGALT grew well, and yeast expressing empty plasmid
with no hGALT, completely failed to grow (Fig. 2). Also as expected,
yeast expressing each of the two hGALT alleles (D28Y and F194L)
that demonstrated >10% residual GALT activity in vitro demonstrated
intermediate growth in the presence of 0.01% galactose (Fig. 2). What
was surprising, however, was that the allele that demonstrated only
marginal residual activity in vitro, R333G, supported growth in theTable 1
GALT activity levels observed in null-background yeast expressing each hGALT allele
from a centromeric plasmid.
hGALT variant Nucleotide change % wild-type activity
(mean ± SD) n = 3
WT N.A. 100 ± 0.00
no GALT N.A. 0.01 ± 0.03
p.D28Y c.82G > T 13.55 ± 5.72
p.L74P c.221T > C 0.01 ± 0.09
p.F171S c.512T > C −0.03 ± 0.01
p.F194L c.580T > C 11.93 ± 2.00
p.R333G c.997C > G 0.60 ± 0.07presence of galactose that was more robust than that seen with either
D28Y or F194L. The explanation for this apparent disparity in yeast
between in vitro and in vivo function for R333G-hGALT remains
unclear but underscores the complexity of the relationship between
mutation, expression, and function in different contexts.
3.4. Expression and puriﬁcation of wild-type and mutant hGALT variants
The His-tagged wild-type and ﬁve mutant proteins were expressed
andpuriﬁedusing amodiﬁed E. coli expression systemalongwith afﬁnity
and size exclusion chromatography. Initial attempts at expression using a
previous protocol [26,27] resulted in small amounts of poor quality puri-
ﬁed protein, which were not amenable to study. Using the E. coli Rosetta
strain coupled with decreasing the induction temperature to 15 °C and
supplementing the growth media with ZnCl2 increased the amount of
expressed protein as judged by SDS-PAGE (data not shown). During ini-
tial puriﬁcation attempts precipitation also occurred frequently during
dialysis, especially when the media or buffers were supplemented with
iron (II) ions. However, decreasing the pre-induction temperature from
37 °C to 30 °C prevented precipitation with ZnCl2-supplemented
media, but not those with FeCl2. This is likely to be due to oxidation of
Fe2+ to Fe3+. In the E. coli enzyme it has been shown that Zn2+ is essen-
tial for maintenance of the structure and that Zn2+ can substitute for
Fe2+ at a second divalent cation binding site [65]. In addition, only
Zn2+ has been conﬁrmed to be present in hGALT [24]. For these reasons
iron supplementation was discontinued. Furthermore size-exclusion
chromatographywas used instead of dialysis to decrease the puriﬁcation
time; this allowed the oligomerisation state of each hGALT variant to be
judged (Fig. 3A, B, C). This protocol resulted in roughly 1.0 mg of highly
puriﬁed hGALT per litre of initial bacterial culture (Fig. 3D).
All hGALT variants were puriﬁed as dimers as judged by size-
exclusion chromatography (Fig. 3C) and each was expressed and pu-
riﬁed successfully using the modiﬁed protocol (Fig. 3D). Notably both
F171S and F194L demonstrated some lower molecular weight con-
taminants, which were likely to be degradation products.
3.5. Kinetic analysis of the forward and reverse reactions on the
recombinant hGALT variants reveals perturbed kinetic constants
Kinetic analysis of both the forward (UDP-Glc + Gal-1P →
UDP-Gal + Glc-1P) and reverse reactions (UDP-Gal + Glc-1P →
UDP-Glc + Gal-1P) was carried out on all hGALT variants. The
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Fig. 3. Expression and puriﬁcation of recombinant hGALT from E. coli using size exclusion chromatography. (A) WT hGALT puriﬁcation was resolved by SDS-PAGE (10%) and
visualised by staining with Coomassie blue. M = molecular mass markers (kDa). (B) Size exclusion chromatography standard curve. The proteins used for standards are as follows
A: Ribonuclease (13.7 kDa); B: Chymotrypsinogen A (25 kDa); C: Ovalbumin (43 kDa); D: Serum albumin (67 kDa) E: Alcohol dehydrogenase (149.5 kDa); F: Thyroglobulin
(669 kDa). (C) Chromatograms of wild-type and mutant hGALT proteins. All the proteins eluted mainly at the expected dimer molecular mass. However p.L74P, p.F171S and
p.F194L showed increases in the absorbance at approximately one column volume suggesting some degradation to smaller peptides had occurred. (D) Puriﬁed hGALT variants re-
solved by SDS-PAGE (10%) and visualised by staining with Coomassie blue. M = molecular mass markers (kDa).
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kinetic models and this depended on the variable substrate (Fig. 4,
Tables 2, 3). In the forward reaction, varying UDP-Glc resulted in
Michaelis–Menten kinetics with substrate inhibition, whereas vary-
ing Gal-1P caused the enzyme to demonstrate classical Michaelis–
Menten kinetics. Kinetic analyses of the reverse reaction revealed
that varying UDP-Gal resulted in sigmoidal kinetics and that varying
Glc-1P ﬁtted best to Michaelis–Menten kinetics with substrate inhibi-
tion. However, the kinetic parameters determined for the wild-type
protein are well within the range of values reported in the literature
[23,26,27,37] and substrate inhibition from both UDP-Glc and
Glc-1P has been reported previously [19,66]. Interestingly hGALT
demonstrated positive cooperativity in the reverse reaction with var-
ied UDP-Gal (Hill coefﬁcient of 2.9 ± 0.3) and although there have
been no deﬁnitive reports of cooperativity for wild-type hGALT,
there have been suggestions of this in puriﬁed heterodimers of
hGALT [12,67]. Submission of the wild-type homology model struc-
ture to three binding site predictors [54,56], resulted in the prediction
of an allosteric site at the dimer interface on the opposite side of the
enzyme to the active sites (Fig. S2).
The variant hGALT proteins demonstrated altered kinetics with
two, p.L74P and p.F171S, showing no detectable activity in both the
forward and reverse assays in the protein concentration range stud-
ied (0 to 0.5 μM). This is in agreement with the yeast lysate activities
(Table 1) along with previous reports that these variants are inactive
[19,20,31]. All other variants showed decreased activity with altered
kinetic parameters and decreased Hill coefﬁcients (Tables 2, 3).
p.D28Y (Fig. S3) had the least altered kcat with only slightly lower ac-
tivity than the wild-type protein. Previously the speciﬁcity constants
have been used as an estimate of the rates of the formation and decay
of the uridyl intermediate [23]. Thus, p.D28Y was impaired in terms
of uridylylation, for both reactions, as judged from the speciﬁcityconstants (Tables 2, 3). This variant was more prone to substrate in-
hibition from UDP-Glc with a Ki value nine times lower than that of
the wild-type. p.F194L (Fig. S4) and p.R333G (Fig. S5), however, did
not show substrate inhibition by UDP-Glc and had much lower activ-
ity than the wild-type and p.D28Y. For both p.F194L and p.R333G,
when UDP-Gal was varied, non-Michaelis–Menten kinetics were ob-
served, with large increases in activity at 700 μM UDP-Gal. This
might be due to these proteins' stabilities during storage; however,
in the lower substrate range both ﬁtted well to the Michaelis–Menten
equation. These variants' speciﬁcity constants revealed different
levels of impairment in uridylylation and deuridylylation for both
reactions and each had altered apparent Km and K0.5 values for all
substrates (Tables 2, 3).
3.6. Chemical cross-linking reveals that substrate binding alters the
dimer interface
GALT only functions as a dimer and both active sites in the holoen-
zyme include residues from both polypeptide chains [10,68,69]; it has
been shown that speciﬁc mutations can affect dimer formation
[12,22,67]. Chemical cross-linking has been a useful tool in determin-
ing whether other mutant proteins, involved in disease, have the po-
tential to oligomerise correctly [70]. Here we employed the cross-
linkers BS3 and glutaraldehyde to investigate the effects of ligands
and point mutations. Both cross-linkers conﬁrmed that all hGALT
variants form dimers (Figs. 5A; S6A) in agreement with the size-
exclusion chromatography experiments (Fig. 3C). Trimers were also
detected with BS3 and other higher molecular weight aggregates were
detected when glutaraldehyde was used. These may be artefactual
due to the high ratio of cross-linker:protein.
Differences in cross-linking were detected in the presence of each
UDP–sugar, sugar–phosphate and appropriate UDP–sugar/sugar–
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Fig. 4. The steady state enzyme kinetics for WT hGALT in the forward and reverse reactions. (A) The steady state enzyme kinetics for WT hGALT in the forward reaction with varied
UDP-Glc and 1 mM Gal-1P. The kinetic data ﬁtted best to the Michaelis–Menten equation with substrate inhibition with the following constants: Kmapp = 81.6 ± 16.3 μM, Kiapp =
850 ± 200 μM, Vmaxapp = 32.2 ± 3.1 μmol Glc-1P min−1 mg−1. (B) The steady state enzyme kinetics in the forward reaction with varied Gal-1P and 500 μM UDP-Glc. The kinetic
data ﬁtted best to the Michaelis–Menten equation with the following constants: Kmapp = 290 ± 40 μM, Vmaxapp = 17.9 ± 0.7 μmol Glc-1P min−1 mg−1. (C) The steady state enzyme
kinetics for WT hGALT in the reverse reaction with varied UDP-Gal and 1 mM Glc-1P. The kinetic data ﬁtted best to the Hill equation (sigmoidal kinetics) with the following con-
stants: K0.5app = 141 ± 5.2 μM, Vmaxapp = 24.6 ± 0.5 μmol UDP-Glc min−1 mg−1, h = 2.9. (D) The steady state enzyme kinetics in the reverse reaction with varied Glc-1P and 500 μM
UDP-Gal. The kinetic data ﬁtted best to the Michaelis–Menten equation with substrate inhibition with the following constants: Kmapp = 159 ± 17 μM, Kiapp = 4.3 ± 0.9 mM.10 nM,
Vmax
app = 27.2 ± 1.0 μmol UDP-Glc min−1 mg−1. WT hGALT (10 nM) was used for both forward and reverse reactions and controls with no GALT always gave no activity. Each point
represents the mean of three independent determinations of the rate and the error bars represent the standard deviations of these means.
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slightly decreased and slightly increased cross-linking was detected
in the presence of a UDP–sugar and sugar–phosphate respectively
(Figs. 6B; S6B). Addition of each UDP–sugar/sugar phosphate pair
resulted in similar levels of cross-linking to protein without substrate.
Each hGALT variant showed similar responses to substrates with
cross-linkers to the wild-type protein, except for the enzymatically
inactive p.L74P and p.F171S. Although these variants could be
cross-linked, little change in the crosslinking pattern was seen in
the presence of ligands (Figs. 5B; S6B). This pattern was similar for
both cross-linkers suggesting that these effects on dimerisation are
due to protein–substrate interactions and not an effect due to the
cross-linker itself.3.7. hGALT mutant proteins show differences in susceptibility to
proteases which is altered in the presence of each substrate
Increased susceptibility to proteases can occur as a consequence of
structural changes due to mutation [71]. Carrying out limited proteol-
ysis using thermolysin and trypsin revealed that p.L74P, p.F171S and
p.F194L have increased susceptibility to proteolytic degradation.
p.R333G showed little change in degradation. In contrast, p.D28Y
was more resistant to degradation (Figs. 6A; S7A). Digestion with
chymotrypsin gave less clear results, but showed that p.D28Y hGALT
is slightly more resistant to degradation whereas p.L74P hGALT is
slightly more susceptible (Fig. S8A).
Since cross-linking was affected by the presence of each substrate,
limited proteolysis was carried out under similar conditions for all
variants. Changes in protease susceptibility in the presence of each sub-
stratewere detected and this followed a similar pattern to that observedin the cross-linking experiments. Increased degradationwas detected in
the presence of both sugar–phosphates, whereas a slight decrease in
degradation occurred with both UDP–sugars. Each UDP–sugar/sugar–
phosphate pair showed similar levels of degradation to protease treated
protein with sugar–phosphate. This pattern occurred for all hGALT vari-
ants except for p.L74P and p.F171S, where the presence of substrate(s)
conferred little, or no, change in degradation (Figs. 6B; S7B). Additionally,
p.F194L demonstrated no increase in degradation in the presence of both
UDP–sugar/sugar–phosphate pair. Again the same results were obtained
for both thermolysin and trypsin, but chymotrypsin resulted in less clear
results for p.F194L and p.R333G (Fig. S8B). The common patterns
resulting from digestion with each protease suggest that these effects
on degradation are due to protein–substrate interactions and not an ef-
fect on the proteases.
These ﬁndings of altered protease stability are in agreement with
the suggestion from in silico analysis that altered protein folding
has occurred, but they do not agree with the overall consensus for
each variant. In addition, the decreased effect on stability from sub-
strates for p.L74P and p.F171S demonstrates that these variants
have altered substrate interactions, agreeing with the cross-linking
and kinetic experiments.3.8. hGALT mutants demonstrate altered intrinsic ﬂuorescence and show
an increased surface hydrophobicity
hGALT contains 24 tryptophan residues per dimer and their excita-
tion resulted in a broad emission spectrum for the wild-type protein
(Fig. S9A). In comparison, all variants studied, except p.D28Y, had in-
creased relative emission intensity suggesting changes in the microen-
vironment of the tryptophans, most likely slight reorientation of one or
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Fig. 5. Chemical cross-linking of hGALT variants with BS3 in comparison to the wild-type hGALT and in the presence of various substrates. (A) The hGALT variants showed little
difference in their ability to form dimers in comparison to the wild-type. Higher order oligomers were also formed in the presence of cross-linker. C: control, protein (5 μM)
with no cross-linker; +: protein (5 μM) with the cross-linker BS3 (100 μM). (B) Active and inactive hGALT variants show different substrate dependent effects on dimerisation
as determined by cross-linking. C: control, protein (5 μM) with no cross-linker; +: protein (5 μM) with BS3 (100 μM) in the presence of various substrates (1 mM). Gal-1P: galac-
tose 1-phosphate; UDP-glc: uridine diphosphate glucose; Glc-1P: glucose 1-phosphate; UDP-gal; uridine diphosphate galactose; For: galactose 1-phosphate and uridine diphos-
phate glucose; Rev: glucose 1-phosphate and uridine diphosphate galactose.
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away from polar quenching groups (Fig. S9A).
In addition, since in silico analysis suggested changes in surface
hydrophobicity, the binding of the hydrophobic ﬂuorescent probe
ANS-1 to each variant was used to investigate any misfolding in the
ground state. All variants except p.D28Y had an increased ANS-1 ﬂuo-
rescence compared to the wild-type protein suggesting p.L74P,
p.F171S, p.F194L and p.R333G hGALT all have larger accessible hydro-
phobic surface areas (Figs. 7A; S9B). These ﬂuorescence results
suggest that all variants tested, except p.D28Y hGALT, have an altered
conformation compared to the wild-type.
3.9. hGALT mutants show altered resistance to thermal denaturation
Thermal stability was ﬁrst determined through thermal inactivation
of enzyme activity. Wild-type hGALT lost activity around 65 °C and
p.D28Y was only slightly more resistant to thermal denaturation.
p.F194L and p.R333G, however, each lost activity at much lower tem-
peratures than the wild-type (50 °C and 55 °C respectively) with
p.R333G showing an inactivation proﬁle with increasing activity up to
45 °C (Fig. 7B).
Since thermal inactivation was only applicable to those mutants
that have activity, differential scanning ﬂuorimetry was carried outon all hGALT variants. This method uses an extrinsic hydrophobic
ﬂuorophore (Sypro orange) to detect unfolding in the presence of
increasing temperature [72]. The melting temperature, Tm, is then cal-
culated as the midpoint between the maximum and initial minimum
ﬂuorescence allowing for comparison of stability between variants.
There is good agreement between DSF and differential scanning
calorimetry [72]. We have previously used this technique to study the
stability changes in human UDP-galactose 4′-epimerase due to ligand
binding and disease-associated mutations [39,40].
Fig. 7C shows the unfolding curves of all six hGALT variants and Tm
values are presented in Table S4. p.F171S was found to have a rela-
tively high initial ﬂuorescence signal at 30 °C as did p.L74P and
p.F194L, to lesser extents. This agrees with the respective ANS-1 ﬂuo-
rescence results; however, p.R333G showed little difference in initial
ﬂuorescence from the wild-type protein and this may be due to dif-
ferences in the binding of ANS-1 and Sypro orange or the starting
temperature of this assay. Thermal denaturation revealed that each
hGALT variant had different Tm values and unfolding proﬁles with
the wild-type having a Tm of 63 °C. p.F194L and p.R333G were less
resistant to denaturation with lower Tm values of 48 °C and 56 °C
respectively. In contrast, p.D28Y was slightly more resistant with a
Tm of 66 °C. p.L74P and p.F171S were also both more resistant to
denaturation with Tm values of 69 °C and 70 °C respectively. These
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Fig. 6. Limited proteolysis of hGALT variants in comparison to the wild-type hGALT and in the presence of various substrates. (A) The hGALT variants showed differences in sus-
ceptibly to degradation by the protease thermolysin in comparison to the wild-type. C: control, protein (5 μM) with no protease; +: protein (5 μM) with thermolysin
(240 nM). (B) WT hGALT showed substrate dependent effects on the susceptibility to proteolysis where sugar 1-phosphates increased degradation and uridine diphosphate sugars
had little effect. Additionally this increased degradation due to sugar 1-phosphates is the most dominant affect when the protein was in the present of both a sugar 1-phosphate
and uridine diphosphate sugar. Active and inactive hGALT variants show different substrate dependent effects on protease sensitivity. C: control, protein (5 μM) with no protease;
+: protein (5 μM)with thermolysin (240 mM) in the presence of various substrates (1 mM). Gal-1P: galactose 1-phosphate; UDP-glc: uridine diphosphate glucose; Glc-1P: glucose
1-phosphate; UDP-gal; uridine diphosphate galactose; For: galactose 1-phosphate and uridine diphosphate glucose; Rev: glucose 1-phosphate and uridine diphosphate galactose.
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together these results demonstrate that each substitution causes
alterations to the thermal stability of the hGALT protein and that
some show misfolding in the ground state.
3.10. Variant hGALT proteins show altered substrate binding
In addition to determining stabilities of proteins, DSF can also pro-
vide information about substrate binding. Here the presence of a sub-
strate can induce conformational changes which can be inferred from
the change in Tm (ΔTm) [73]. Tables 4 and S4 present the ΔTm and Tm
values of each hGALT variant in the presence of various substrates.
Fig. 7D shows the unfolding curves of WT hGALT in the presence of
UDP-Glc and Gal-1P. Wild-type and p.D28Y hGALT showed similar,
statistically signiﬁcant increases in stability in the presence of all sub-
strates. Here both Glc-1P and Gal-1P resulted in similar ΔTm values of
approximately 6.5 K whereas UDP-Glc and UDP-Gal resulted in ΔTm
values of approximately 2.5 K. Both substrate pairs that resulted in
similar increases of stability of 6.5 K. p.L74P and p.F171S differed,
showing no signiﬁcant changes in stability with each substrate indi-
vidually, although p.L74P appeared to be slightly destabilised in the
presence of both substrate pairs (ΔTm of −1.5 K). p.F194L also
showed increases in stability for all substrates, but not to the sameextent as the wild-type protein. This variant showed decreased stabil-
ity with both sugar phosphates (ΔTm of 1.9 K), UDP-Gal (ΔTm of
0.5 K) and both substrate pairs (ΔTm of 2.2 K). Interestingly,
p.R333G showed the most different behaviour when compared to
the wild-type protein. The presence of UDP-Gal and Gal-1P resulted
in no signiﬁcant changes, whereas UDP-Glc resulted in an increase
of 1.6 K and Glc-1P caused a decrease of−2.0 K. Additionally changes
in stability in the presence of each substrate pair appeared to be the
sum of the results of each substrate on its own.
Overall these results indicate that the D28Y substitution does not
cause any signiﬁcant changes in substrate binding, whereas both
L74P and F171S appear to cause a substantially decreased ability to
bind substrates. p.F194L and p.R333G hGALT still have the ability to
bind substrates but not to the same extent as the wild-type protein.
4. Discussion
4.1. Structural bioinformatics analyses reveal further details of the effects
of each substitution on hGALT structure and function
A previous study used a homology model of hGALT to study the
structural effects of 107 disease-associated variants of hGALT (http://
bioinformatica.isa.cnr.it/GALT/) [29]. The structures of p.D28Y, p.L74P,
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Fig. 7. Surface hydrophobicity and thermal stability of hGALT variants. (A) Relative surface hydrophobicity of each hGALT variant as judged by ANS-1 binding. The emission (at
480 nm) of ANS-1 binding was measured following excitation at 370 nm. The average ﬂuorescence and standard deviation were calculated from three independent assays with
each corrected for ANS-1 alone. The signiﬁcance of change in ﬂuorescence in comparison to the wild-type was determined using one-way ANOVA with a Dunnett's post-test.
(B) Thermal inactivation of wild-type hGALT and active variants (p.D28Y, p.F194L and p.R333G) at 50 nM. Aliquots (100 μl) of each variant hGALT (0.5 μM) were incubated in
HEPES (10 mM), pH 8.8 for 15 min at temperatures ranging from 30 to 70 °C. Residual activity of the forward reaction was determined with 0.5 mM UDP-Glc and 1.0 mM
Gal-1P. Activities were normalized to those at 30 °C. Three independent assays for each temperature were carried out and the points show the average activity and the error
bars show the standard deviations of these means. (C) Each hGALT variant showed a unique melting curve and susceptibility to thermal denaturation as judged by DSF. Melting
temperatures, (Tm) are presented in Table S2. (D) Melting proﬁles and melting temperatures of WT hGALT with and without Gal-1P or UDP-Glc. WT hGALT showed a shift in sta-
bility when Gal-1P or UDP-Glc was present consistently with binding to the substrate and consequent stabilisation of the substrate. Melting temperatures, (Tm) are presented in
Table S2. Reaction mixtures contained 5 μM protein, 1 mM ligand and 2.5× Sypro orange (manufacturer's concentration deﬁnition) dissolved in 10 mM HEPES pH 8.8. Controls
contained no protein. Assays were set up in triplicate and the curves were constructed from the mean ﬂuorescence values; the error bars represent the standard deviations of
these means.
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dicted structures allow for amore in-depth analysis of how thesemuta-
tions cause their effects.
Asp-28 is located towards the N-terminus and near the dimer in-
terface but is not part of the active site. This residue forms a salt
bridge with Arg-25 (Fig. 8A) and its alteration to tyrosine is predicted
to have no direct effects on substrate interaction. However, Asp-28
also forms a salt bridge with His-47 and this residue is in the same
loop as Arg-48 and Arg-51 that are predicted to form contacts with
the sugar and phosphate moieties of the opposite subunit's active
site [29,69]. Mutating Asp-28 to tyrosine removes these salt bridges
(Fig. 8B). It has been shown that this loop containing equivalent res-
idues in E. coli GALT shows different conformations in the different
crystal structures, being partially disordered, and this is possibly
due to interactions between it and the substrate [19,29]. It has been
suggested that this loop is involved in excluding water from the ac-
tive site preventing the hydrolysis of the uridyl-enzyme and partici-
pating in its energetically unfavourable formation [65].
Our studies on the wild-type protein suggest that conformational
changes are important in substrate binding, most likely in these active
site loops (Figs. 5B, 6B, S6B, S7B, S8B, Table 4). These loops in p.D28Y
are likely to be less ﬂexible due to the removal of a connection to the
highly ﬂexible N-terminus as determined from predicted regions of
disorder of WT hGALT (Fig. S10). This increases the enzyme's overallstability (Figs. 5A, S7A, S8A, 7C), but causes little change in the overall
global conformation of the protein (Figs. 7A, S9). The decreased
ﬂexibility reduces the likelihood of the release of UDP-Glc and Glc-1P
thus increasing the apparent inhibition from these substrates
(Tables 2,3), explaining the kinetic impairment. This is not the ﬁrst re-
port of an hGALT variant showing increased inhibition and stability: a
patient's hGALT was more prone to substrate inhibition by Glc-1P
and was more thermally stable than the wild-type protein [74]. The
speciﬁc mutations involved were not identiﬁed but it is likely that
they affected these active site loops. In addition, since p.D28Y appears
to affect the other subunit's active site it can be predicted that this mu-
tation may be dominantly negative and this further supports the hy-
pothesis that there is communication between the active sites.
Leu-74 is located at the dimer interface and active site of hGALT
(Fig. 8C). This residue's carbonyl oxygen hydrogen bonds with the
side chains of both Cys-130 and Tyr-89, whereas the backbone nitrogen
hydrogen bonds to the side chain of Asn-72. The residue is predicted to
be located close to the uracil moiety and it has been suggested that mu-
tating this residue to proline removes van derWaal's contacts between
the residue and this part of the substrate [10]. Mutating this leucine to
proline only appears to remove the hydrogen bond with Asn-72 on
the same polypeptide chain (Fig. 8D), as proline's backbone nitrogen
cannot hydrogen bondwith hydrogen. Leu-74 is ﬂanked by a conserved
cysteine and proline [31] and the introduction of an additional proline
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a
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Trp41b
Lys120a
Tyr339bLeu43bIle32b His186a
Ser192a
Leu194a
Asp197a
Trp41b
Tyr339bLeu43bIle32b
Asn97 Asn97
Fig. 8. Amino acids affected by hGALT mutations affect side-chain and substrate interactions. (A) Asp-28 is located in the N-terminal loop at the dimer interface and forms a number
of hydrogen bonds, one of which is with His-47. This residue is on the same loop as Arg-48 and Arg-51 that form part of subunit B's active site. (B) p.D28Y results in the removal of
the interaction between this residue and His-47. (C) Leu-74 is located at the active site and is ﬂanked by Pro-73 and Cys-75. This residue forms hydrogen bonds with Cys-130 and
Tyr-89 via its backbone oxygen and with Asn-72 via the backbone nitrogen. (D) p.L74P results in the removal of the hydrogen bond with Asn-72. Leu-74 is predicted to be close to
the uracil moiety of UDP-Glc and possibly interacts hydrophobically. (E) The residue Phe-171 is located at the active site and the dimer interface. It is close to Gln-188 and forms
only backbone interactions with this residue. (F) p.F171S results in an additional hydrogen bond between the side chain hydroxyl and backbone oxygen of Met-298. (G) Phe-194 is
located at the dimer interface and exterior of hGALT. This residue forms hydrogen bonds between its backbone oxygen with the hydroxyl of Ser-192. The side chain of Phe-194 is
buried in a largely hydrophobic cleft containing residues from both polypeptide chains. (H) p.F194L results in a smaller side chain that points more towards the exterior of the pro-
tein. (I) Arg-333 is predicted to be part of a number of loops at the dimer interface between the two active sites. This residue is facing the Arg-333 of the other subunit and beside
Lys-334 that is predicted to interact with the sugar moiety of either substrate [29]. (J) Alteration of arginine to glycine at residue 333 results in a void at the dimer interface due to
the smaller size of the side chains. Subunit backbones are ribbon representations with subunit A in pale green and subunit B in light orange. Selected residues are shown as stick
models in white with nitrogen, oxygen, phosphate and sulphur atoms in blue, red, orange and yellow respectively. Residues affected by mutation are in dark grey and hydrogen
bonds are shown as black dotted lines. His-186 is shown in purple and the substrate UDP-Glc is shown in cyan. Structures are from the hGALT structure [28].
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resulting in a more rigid structure. Additionally this variant is also pre-
dicted to affect the ﬂexibility of Asn-97 (Fig. S10B), a residue thatmakes
multiple contacts with the nucleotide moiety of UDP-Gal (Fig. 8D). ThisTable 2
Steady state kinetic constants for the forward reaction of recombinant wild-type and active
hGALT variant Apparent Km
μM
UDP-G
μM
UDP-Glc a Gal-1Pb
WT 81.6 ± 16.3 290 ± 40 850 ±
p.D28Y 448.7 ± 231.4 288 ± 64.6 94 ± 4
p.F194L 60.8 ± 10.9 45.9 ± 25.4 N.D.
p.R333G 285.7 ± 87.5 1184 ± 216 N.D.
a [Gal-1P] = 1000 μM.
b [UDP-Glc] = 500 μM.interpretation agrees well with our in vitro ﬁndings that demonstrate
that this variant is misfolded (Figs. 6, 7A, S7A, S8A, S9), yet thermally
stabilised (Fig. 7C, Table S4). Therefore this substitution is likely to
cause a conformational change at the active site resulting in impropervariant hGALT enzymes.
lc Ki Apparent kcat
s−1
Apparent kcat/Km
×105 l mol−1 s−1
UDP-Glca Gal-1Pb
200 13.6 ± 0.5 1.67 ± 0.34 0.47 ± 0.07
8 9.4 ± 0.7 0.21 ± 0.11 0.33 ± 0.08
2.5 ± 0.1 0.41 ± 0.08 0.54 ± 0.30
0.98 ± 0.12 0.03 ± 0.01 0.008 ± 0.001
Table 3
Steady state kinetic constants for the reverse reaction of recombinant wild-type and active variant hGALT enzymes.
hGALT variant Apparent Km or K0.5
μM
Glc-1P Ki
mM
UDP-Gal h Apparent kcat
s−1
Apparent kcat/Km or kcat/K0.5
×105 l mol−1 s−1
UDP-Gal a Glc-1P b UDP-Gal a Glc-1P b
WT 141 ± 5.2 159 ± 17 4.3 ± 0.9 2.9 ± 0.3 17.7 ± 0.4 1.26 ± 0.05 1.11 ± 0.12
p.D28Y 179 ± 12 121 ± 24.9 2.3 ± 0.6 1.4 ± 0.1 9.3 ± 0.3 0.52 ± 0.03 0.77 ± 0.16
p.F194L 89.7 ± 5.7 118 ± 14.4 3.2 ± 0.7 1.8 ± 0.2 5.5 ± 0.1 0.61 ± 0.04 0.47 ± 0.06
p.R333G 324.4 ± 33.6 202.1 ± 17.9 5.9 ± 1.2 1.6 ± 0.2 5.5 ± 0.3 0.16 ± 0.02 0.27 ± 0.03
a [Glc-1P] = 1000 μM.
b [UDP-Gal] = 500 μM.
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S7B, S8B, Table 4).
Phe-171 is also located at the dimer interface and active site as
judged from the homology model of hGALT (Fig. 8E). This residue
forms a hydrogen bondwithGln-188 of the same subunit and its phenyl
side chain is close to both Asn-172 and Tyr-339 of the other polypeptide
chain. Asn-172 forms hydrogen bonds to the phosphate moiety of the
substrate and Gln-188 is predicted to favour the nucleophilic attack of
sugar 1-phosphates on the uridylated enzyme and also stabilises the
uridylated intermediate [27,75]. Previous studies have predicted that
this mutation displaces Gln-188 and forms new bonds between it and
the hydroxyl of Ser-171 [19]. In contrast, more recent modelling pre-
dicted that this hydrogen bond forms between the serine hydroxyl
and the carbonyl oxygen of the backbone of Met-298 [29] (Fig. 8F).
This repositioningwould have severe effects on activity as has been pre-
viously determined for thismutant protein [19,20]. In addition, this sub-
stitution replaces a hydrophobic residue with a polar residue, which
may contribute to more general misfolding.
It has been suggested that this mutation affects the secondary
structure of this region of the protein, since serine does not favour
the formation of β-sheets [19]. Consistent with this, F171S is predict-
ed to increase the disorder of this region (Fig. S10B) and is thus likely
to contribute to misfolding of the protein. In this study p.F171S
showed similar effects on enzyme function to p.L74P, as expected
considering their similar location in the enzyme (Figs. 5, 6, S6, S7,
S8, S9; Table 4). p.F171S is likely to cause similar conformational
changes in the active site and results in a protein which is misfolded
as suggested from its higher surface hydrophobicity (Fig. 7A, C). This
variant was suggested to be incapable of substrate binding [19] and
our results are in agreement with this prediction.
Phe-194 is at the dimer interface and not at the active site (Fig. 8G).
The backbone of this phenylalanine forms a hydrogen bond with
Ser-192 of the same monomer. Importantly, the side chain of Phe-194
is buried in a largely hydrophobic cleft containing residues from both
polypeptide chains: Leu-102a, Ala-122a, Ser-192a, Pro-196a, Ile-32b,
Leu-43b and Tyr-339b (where a and b represent residues from the
two subunits). Substitution to leucine at this position alters these hy-
drophobic interactions as its side chain points away from this cleftTable 4
Change of melting temperatures ΔTm of recombinant wild-type and variant hGALT enzyme
ΔTm (K)
hGALT variant +Gal-1P +UDP-Glc +Glc-1P
WT 6.5 ± 0.6⁎⁎⁎ 2.5 ± 0.8⁎⁎⁎ 6.5 ± 0.4⁎⁎⁎
p.D28Y 8.8 ± 1.0⁎⁎⁎ 3.2 ± 1.4⁎⁎⁎ 8.0 ± 1.9⁎⁎⁎
p.L74P −0.7 ± 0.9 −0.6 ± 1.0 −0.3 ± 1.1
p.F171S −0.3 ± 1.4 −0.3 ± 0.9 0.1 ± 0.9
p.F194L 1.9 ± 0.5⁎⁎⁎ 1.6 ± 0.1⁎⁎⁎ 1.3 ± 0.5⁎⁎⁎
p.R333G −1.1 ± 2.0 1.6 ± 0.8⁎ −2.0 ± 0.9⁎⁎
All ligands were added to a ﬁnal concentration of 1 mM in 10 mM HEPES, pH 8.8. ΔTm valu
⁎ P b 0.05 (one way ANOVA with Dunnett comparison test).
⁎⁎ P b 0.001 (one way ANOVA with Dunnett comparison test).
⁎⁎⁎ P b 0.0001 (one way ANOVA with Dunnett comparison test).resulting in increased solvent accessibility (Fig. 8H). This is also predict-
ed to cause a slight decrease in the ﬂexibility of the active site residue
His-186 (Fig. S10B). These structural predictions agree well with our
in vitro ﬁndings, which showed a higher surface hydrophobicity (Fig.
7A, C) and decreased thermal stability (Fig. 7B, C). Therefore this region
of the protein must be important in stability and this mutation is likely
to cause conformational changes as suggested from this variant's in-
creased intrinsic ﬂuorescence (Fig. S9) and decreased resistance to pro-
teolysis (Figs. 6, S7, S8). Unlike the active site loops this section of the
protein is highly ordered forming the scaffold for the active site [29].
Misfolding of this section is likely to cause a conformational change at
the active site, altering substrate binding (Figs. 5B, 6B, S6B, S7B, S8B,
Table 4) and decreasing activity (Tables 2 and 3).
Arg-333 is at the dimer interface between the two active sites
of the enzyme (Fig. 8I). This residue faces Arg-333 of the other mono-
mer and appears not to be involved in any interactions. Alteration of
this residue to the smaller glycine results in a large void in the middle
of the hGALT dimer (Fig. 8J) although not directly affecting any resi-
dues in the active site. However, adjacent to this residue is Lys-334,
which is predicted to form hydrogen bonds to the hydroxyl groups
of the sugar moiety of each substrate. Interestingly the E. coli struc-
ture demonstrates slight conformational changes depending on the
position of the 4′-hydroxyl group of the substrate's sugar moiety.
This change is predominantly at Glu-317 of the bacterial enzyme
and suggests that the corresponding residue in the hGALT, Glu-340,
interacts with Lys-334 (Lys-311 in bacterial GALT) only when
hGALT is UDP-Gal bound. This lysine also interacts with 3′- and 4′-hy-
droxyl groups of both UDP–sugars [69]. Arginine side chains are large
and Arg-333 possibly reduces the ﬂexibility of this region due to the
requirement to avoid steric clashes with the equivalent arginine of
the other subunit. Changing either residue to glycine decreases this
residue's size and possibly alters that subunit's ﬂexibility at that loca-
tion. Predictions, however, suggested that this alteration slightly de-
creases the ﬂexibility of this region (Fig. S10B). This alteration of the
ﬂexibility, and the void created, may explain this mutant's decreased
thermal stability (Fig. 7; Table S4), its increased surface hydrophobic-
ity (Fig. 8A) and its altered intrinsic ﬂuorescence (Fig. S9A). Altered
ﬂexibility may also cause Lys-334 to change its interaction withs in the presence of various substrates.
+UDP-Gal +Gal-1P & UDP-Glc +Glc-1P & UDP-Gal
2.5 ± 0.6⁎⁎⁎ 6.1 ± 0.4⁎⁎⁎ 6.6 ± 0.8⁎⁎⁎
2.2 ± 1.5⁎ 8.0 ± 1.5⁎⁎⁎ 8.2 ± 1.1⁎⁎⁎
−1.4 ± 0.9 −1.5 ± 0.7⁎ −1.5 ± 0.7⁎
−0.4 ± 1.0 0.0 ± 0.9 0.5 ± 1.0
0.5 ± 0.0 2.1 ± 0.2⁎⁎⁎ 2.5 ± 0.0⁎⁎⁎
−0.2 ± 0.8 0.3 ± 0.7 −2.0 ± 0.8⁎
es are reported as the means ± SD of three separate experiments.
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change when the enzyme binds a substrate. This may explain
p.R333G's severely impaired activity in vitro (Tables 2,3) and the ef-
fects on substrate binding (Figs. 5B, 6B, S6B, S7B, S8B, Table 4). The
observation of non-Michaelis–Menten kinetics for both F194L and
R333G (Tables 2,3) may also be due to their increased ﬂexibilities.
4.2. The hGALT variants show characteristics of protein misfolding
As a large majority of disease-associated mutants of hGALT are not
located at the active site it has been suggested that they are likely to
cause their affects by protein misfolding [15,29]. In this scenario alter-
ation of the protein sequence reduces the amount of active protein by
conformational changes that perturb the active site, thus impairing
substrate binding, the formation and decay of the uridylated interme-
diate and altering the protein's overall stability. Taken together this
study of ﬁve hGALT mutants has demonstrated that each causes
unique changes of these aspects of the protein. All these effects are
not mutually exclusive and are caused by the removal of important
interactions involved in the protein structure and in substrate bind-
ing. From this it can be concluded that protein misfolding is the un-
derlying reason for these mutants' enzymological impairment and
adds compelling evidence to this being a common molecular mecha-
nism of hGALT deﬁciency in patients.
The contribution of uridyl-enzyme intermediate also needs to be con-
sidered. hGALT has been shown to be present in vivo as a mixed popula-
tion of uridylated and deuridylated enzyme [25]. As such it is likely that
the puriﬁed hGALT variants in this study are amixed population of these
states. However, there is some uncertainty about the stability of the in-
termediate as it has been shown kinetically that UMP can dissociate to
reform the free enzyme [27]. Interestingly if the uridylated enzyme is
stable there are some hints of the effects of uridylation in the data
presented here. Both p.L74P and p.F171S are inactive variants and prob-
ably do not form the covalent intermediate (similar to the inactive, arti-
ﬁcial variant p.H186G [25]). p.L74P andp.F171S showed a similar level of
degradation by proteases (Figs. 6A, S7A) and melting temperatures
(Table S4) as the wild-type in the presence of a sugar 1-phosphate. The
effects seen in this study on stability from sugar-1-phosphates may be
due to deuridylation and the effects of UDP–sugars could be due to
dead-end binding [19]. p.L74P and p.F171S may be misfolded and
trapped in a deuridylated state. Thus, those variants that are impaired
in the formation of the intermediatemay bemore prone to protease deg-
radation. Further investigation of the contribution of the covalent inter-
mediate to enzyme stability is required.
4.3. Altered substrate binding: A consequence of protein misfolding
It has been shown that the ability to rescue galactose stressed
null-GALT yeast correlates with each variant's activity [20]. This was
observed for all variants in this study except for p.R333G (Table S3B;
Fig. 2). However this is not the ﬁrst time that a disparity of this relation-
ship has been found [20] and it is likely that somevariants aremore sen-
sitive to cellular environmental factors as also seen with UDP-galactose
4′-epimerase [35]. Activities in yeast lysates also correlated well with
those of the puriﬁed protein and it appears that enzyme activity is
roughly correlated with substrate binding and not overall stability as
determined by DSF. Inactive variants p.L74P and p.F171S show little
change in thermal stability whereas the least impaired variant, p.D28Y,
shows similar changes to the wild-type protein. p.F194L was the second
most impaired active variant and showed clear, but lower, stability
changes than the wild-type protein. The least active variant, p.R333G,
showed even smaller changes in stability following substrate binding.
This agrees with recent molecular dynamic simulations that predicted
that the wild-type protein demonstrates a conformational change, be-
coming more compact when bound to UDP-Gal. Variants were predict-
ed to be initially in a more compact structure before UDP-Gal bindingand/or did not demonstrate a conformational change after binding
suggesting an alteration of substrate binding is the cause of their im-
pairment [30].
4.4. Conclusions
Since a common molecular mechanism of hGALT deﬁciency ap-
pears to be protein misfolding it may be possible to develop “pharma-
cological chaperone” treatments. Here a small ligand binds at the
active site or novel binding pocket causing conformation changes
that increase the stability and activity of the protein. This treatment
is already used in phenylketonuria and has been suggested for other
diseases [76–78]. Such small molecules usually bind to cofactor or
substrate binding sites and the latter may be appropriate for hGALT.
In addition, using the homology model 1R3A and three different bind-
ing site predictors [54,56] (Fig. S2), we have identiﬁed an additional
binding pocket at the dimer interface, on the opposite side of the ac-
tive sites. The possible biological function of this predicted binding
pocket is not known, but it may be involved in allosteric control of
this enzyme (Fig. 4C). The detection of non-Michaelis–Menten kinet-
ics suggests the potential for allosteric activation or repression. This
pocket could be targeted for pharmacological chaperone treatment.
In addition the use of proteostasis regulators may also beneﬁcial, de-
creasing the rate of degradation of unstable mutant proteins [79].
Such therapies for galactosemia sufferers may alleviate the severity
of the disease's acute or long-term pathology and/or allow for some
relaxation of galactose restricted diets. Interestingly this mechanism
of a ligand-mediated increase in stability has been used to explain
the ﬁndings of increased hGALT activity in HepG2 cells in the pres-
ence of high concentrations of galactose [80].
In summary we have measured the level of impairment of ﬁve
hGALT variants in a yeast model. Further research on the recombinant
puriﬁed proteins demonstrated that these hGALT variants are structur-
ally altered, which affects thermal stability and protease resistance.
This, in turn, results in their decreased ability to bind substrates and
lower enzymatic activity. These new insights have revealed that the
molecular basis of these variants' altered activity is due to protein
misfolding and strongly suggests that this is a common, underlying
cause of hGALT deﬁciency in type I galactosemia. In view of these ﬁnd-
ings we suggest that both pharmacological chaperone and proteostasis
regulator treatments should be investigated.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.04.004.
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